This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Fluoroquinolone antibiotics - restrictions and precautions due to very rare reports of disabling and potentially long-lasting or irreversible side effects

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Systemic and inhaled fluoroquinolones are associated with a risk of serious, disabling, long-lasting and potentially irreversible adverse reactions, estimated to occur in at least between 1 and 10 people in every 10,000 who take a fluoroquinolone (1):

  • may affect multiple body systems and include musculoskeletal, nervous, psychiatric and sensory reactions
  • adverse reactions have been reported in patients irrespective of their age and potential risk factors.
  • patients have reported that experiencing long-lasting or disabling reactions can affect their mental health, particularly when they perceive healthcare professionals fail to adequately acknowledge the reactions or the possibility that they are associated with a fluoroquinolone
  • tendon damage can occur within 48 hours of commencing treatment, or the effects can be delayed for several months and become apparent after stopping treatment
  • are no proven drug treatments for these side effects
    • however, it is important that fluoroquinolones are stopped immediately at the first signs of a musculoskeletal, neurological or psychiatric side effect, such as those described above to avoid further exposure, which could potentially worsen adverse reactions
    • these symptoms should be appropriately investigated

  • Advice for healthcare professionals (1):

  • systemic (by mouth, injection, or inhalation) fluoroquinolones can cause long-lasting (up to months or years), disabling and potentially irreversible side effects, sometimes affecting multiple body systems and senses
  • the UK indications for systemic fluoroquinolones have been updated so they must only be used in situations when other antibiotics, that are commonly recommended for the infection, are inappropriate
  • situations in which other antibiotics are considered to be inappropriate and where a fluoroquinolone may be indicated are where:
    • there is resistance to other first-line antibiotics recommended for the infection
    • other first-line antibiotics are contraindicated in an individual patient
    • other first-line antibiotics have caused side effects in the patient requiring treatment to be stopped
    • treatment with other first-line antibiotics has failed
  • this goes further than previous measures which set out that fluoroquinolones should not be prescribed for non-severe or self-limiting infections, or non-bacterial conditions, for example non-bacterial (chronic) prostatitis. These measures are still in place
  • as a reminder, patients should be advised to stop fluoroquinolone treatment at the first signs of a serious adverse reaction, such as tendinitis or tendon rupture, muscle pain, muscle weakness, joint pain, joint swelling, peripheral neuropathy and central nervous system effects, and to contact their doctor immediately
  • refer to MHRA’s sheet for patients for further advice
  • remain alert to the risk of suicidal thoughts and behaviours with use of fluoroquinolone antibiotics - see https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-suicidal-thoughts-and-behaviour
  • advice published in August 2023 issue states:
    • avoid fluoroquinolone use in patients who have previously had serious adverse reactions with a quinolone antibiotic (for example, nalidixic acid) or a fluoroquinolone antibiotic
    • prescribe fluoroquinolones with special caution for people older than 60 years and for those with renal impairment or solid-organ transplants, because they are at a higher risk of tendon injury
    • avoid coadministration of a corticosteroid with a fluoroquinolone since this could exacerbate fluoroquinolone-induced tendinitis and tendon rupture

A study showed no increased risk of aortic aneurysm and aortic dissection (AA/AD) associated with fluoroquinolone (FQ) use (2).

Reference:

  • MHRA - Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate. Drug Safety Update volume 17, issue 6: January 2024: 2.
  • Hung K et al. Lack of association between fluoroquinolone and aortic aneurysm or dissection, European Heart Journal, 2023;, ehad627, https://doi.org/10.1093/eurheartj/ehad627

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.